Gritstone Bio

Gritstone Bio is a biotech company in Emeryville, United States, founded in 2015. It has raised $92.7M across 1 round, most recently a $92.7M Series B in September 2017.

Home - Nexoplex Bio

Employees
201–500
Founded
2015
Business Model
B2B
Total Funding
$92.7M
Last Round
$92.7M Series BSep 2017
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

Gritstone Bio, now operating as Nexoplex Bio after emerging from Chapter 11, develops next-generation cancer immunotherapies. The company focuses on multi-specific and bispecific antibodies that bind tumor targets and on generating potent, durable immune responses by targeting select antigens, including tumor-specific peptide–HLA complexes. Its scientific approach aims to help the immune system recognize and destroy diseased cells and to advance treatments for unmet needs in oncology.

Summary

It lists 201–500 employees. It has raised $92.7M in total across 1 round, most recently a $92.7M Series B round in Sep 2017.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BSep 2017
$92.7M

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences
Series CTotal funding$955.0MSep 2024

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gritstone Bio on Indexed.vc
<a href="https://indexed.vc/companies/gritstone-bio"><img src="https://indexed.vc/api/badge/company/gritstone-bio" alt="Gritstone Bio on Indexed.vc" width="260" height="76" /></a>